Article in mSphere, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
22 authors.
Marco FabbriniUnit of Microbiome Science and Biotechnology, Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.ORCID 0000-0003-1431-0643
Federica D'AmicoHuman Microbiomics Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.ORCID 0000-0002-2136-9558
Bernardina T F van der GunDepartment of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Monica BaroneHuman Microbiomics Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.ORCID 0000-0001-5229-570X
Gabriele ContiUnit of Microbiome Science and Biotechnology, Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.ORCID 0000-0002-4623-043X
Sara RoggianiUnit of Microbiome Science and Biotechnology, Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.ORCID 0009-0008-2455-6624
Karin I WoldDepartment of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
María F Vincenti-GonzalezDepartment of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Gerolf C de BoerDepartment of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.ORCID 0009-0002-4186-270X
Alida C M VelooDepartment of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.ORCID 0000-0002-0095-8740
Margriet van der MeerDepartment of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Elda RighiDepartment of Diagnostics and Public Health, Infectious Diseases Department, University of Verona, Verona, Italy.ORCID 0000-0001-8718-1200
Elisa GentilottiDepartment of Diagnostics and Public Health, Infectious Diseases Department, University of Verona, Verona, Italy.ORCID 0000-0001-6018-5295
Anna GórskaDepartment of Diagnostics and Public Health, Infectious Diseases Department, University of Verona, Verona, Italy.ORCID 0000-0003-3305-8711
Fulvia MazzaferriDepartment of Diagnostics and Public Health, Infectious Diseases Department, University of Verona, Verona, Italy.
Lorenza LambertenghiDepartment of Diagnostics and Public Health, Infectious Diseases Department, University of Verona, Verona, Italy.
Massimo MirandolaDepartment of Diagnostics and Public Health, Infectious Diseases Department, University of Verona, Verona, Italy.ORCID 0000-0002-2342-5867
Maria MongardiDepartment of Diagnostics and Public Health, Infectious Diseases Department, University of Verona, Verona, Italy.ORCID 0009-0000-5731-5212
Evelina TacconelliDepartment of Diagnostics and Public Health, Infectious Diseases Department, University of Verona, Verona, Italy.ORCID 0000-0003-2010-4977
Silvia TurroniUnit of Microbiome Science and Biotechnology, Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.ORCID 0000-0003-2345-9482
Patrizia Brigidi *Human Microbiomics Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.ORCID 0000-0001-8375-6150
Adriana Tami *Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.ORCID 0000-0002-1918-9144
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Several studies reported alterations of the human gut microbiota (GM) during COVID-19. To evaluate the potential role of the GM as an early predictor of COVID-19 at disease onset, we analyzed gut microbial samples of 315 COVID-19 patients that differed in disease severity. We observed significant variations in microbial diversity and composition associated with increasing disease severity, as the reduction of short-chain fatty acid producers such as
Indexed as
COVID-19Gastrointestinal MicrobiomeSARS-CoV-2Severity of Illness IndexAdultAgedBacteriaBiomarkersFecesFemaleHumansMachine LearningMaleMiddle AgedBiomarkersCOVID-19 severitygut microbiotamachine learning
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The gut microbiota as an early predictor of COVID-19 severity. · full record | OpenQuestion